US EditionPublished • loading... • Updated
Health Check: Biotechs canter into November, but the ‘favourites’ have lead in their saddlebags
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Health Check: Biotechs canter into November, but the ‘favourites’ have lead in their saddlebags
Optiscan Imaging led the biotech pack in October, while some of the Big Four stocks were late scratchings Does CSL have an iron deficiency? Weebit Nano ‘mini me’ Dorsavi quietly jockeys for position in the high-stakes chip race The ASX-listed life sciences sector galloped nicely in October, albeit weighed down by the performance of the ‘Big Four’ stocks. On Biotech Daily’s reckoning the top 40 stocks gained an average 7.6% for the month, for a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
